Aneurysmal subarachnoid hemorrhage/neurocritical care Nervous System Diseases Subarachnoid haemorrhage
Conditions
Interventions
Objective 1 will be to examine by flow cytometry the temporal evolution of endothelial, platelet-, leukocyte-, and erythrocyte-derived microparticles in patients with aneurysmal subarachnoid hemorrhag
neuroimaging studies will be performed at admission [baseline] to confirm the diagnosis, after aneurysm repair [i.e., within 24 hours], at day 8 ± 2, day 14 ± 2, day 21 ± 2 and day 90 ± 7
additional neuroimaging studies indicated at the discretion of the treating physicians are permitted). All patients will be followed for at least 3 months.
Objective 3 will correlate the potential qu
Sponsors
Austrian Science Fund (FWF) (Austria)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients of either sex aged between 18?75 years 2. Signs and symptoms of SAH with an onset within 48 hours before screening irrespective of World Federation of Neurological Surgeons (WFNS) grade (I?V) at admission 3. A computed tomography (CT) scan shows an aneurysmal bleeding pattern in combination with the presence of an appropriate aneurysm at CT angiography or digital subtraction angiography (DSA) 4. Women of childbearing potential must have a negative serum pregnancy test
Exclusion criteria
Exclusion criteria: 1. Definite contraindication to magnetic resonance imaging (MRI) (e.g., pacemakers) 2. History of trauma, cerebral vascular malformation or other non-aneurysmal source of bleeding 3. Moderate to severe cerebral vasospasm at screening 4. Known coagulopathies, long-term therapy with platelet aggregation inhibitors or oral anticoagulants 5. Severe concomitant diseases as well as patients in whom death seems imminent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prognostic value of cellular microparticles for the occurrence of cerebral infarction attributable to delayed cerebral ischemia (i.e., not adjudicated to lesions arising from the aneurysm repair procedure, intracerebral hemorrhage or ventricular drain encephalomalacia) assessed by magnetic resonance imaging (MRI) at day 21 ± 2. | — |
Secondary
| Measure | Time frame |
|---|---|
| Association of cellular microparticles with patient morbidity and mortality at the 3-month follow-up visit. Other (exploratory) endopoints, derived from the clinical database, might be analyzed on data-driven considerations. | — |
Countries
Austria
Outcome results
None listed